Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
about
Q24197685Review of depot aripiprazole for schizophreniaPimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disordersChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureResource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).Getting less of what you want: reductions in statistical power and increased bias when categorizing medication adherence data.Feasibility, acceptability, and preliminary efficacy of a smartphone intervention for schizophrenia.CrossCheck: Integrating Self-Report, Behavioral Sensing, and Smartphone Use to Identify Digital Indicators of Psychotic Relapse.The cost of relapse and the predictors of relapse in the treatment of schizophreniaCoverage of atypical antipsychotics among medicare drug plans in the state of washington: changes between 2007 and 2008.Definitions and drivers of relapse in patients with schizophrenia: a systematic literature reviewAssessing medication adherence and healthcare utilization and cost patterns among hospital-discharged patients with schizoaffective disorder.Resource utilization and cost in a commercially insured population with schizophreniaAntipsychotic treatments for the elderly: efficacy and safety of aripiprazole.Predicting Future High-Cost Schizophrenia Patients Using High-Dimensional Administrative Data.Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophreniaLong acting risperidone in Australian patients with chronic schizophrenia: 24-month data from the e-STAR databaseMedication adherence and its determinants among psychiatric patients in an Ethiopian referral hospital.Medication adherence and utilization in patients with schizophrenia or bipolar disorder receiving aripiprazole, quetiapine, or ziprasidone at hospital discharge: a retrospective cohort study.Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study.Attitudes towards the administration of long-acting antipsychotics: a survey of physicians and nursesImpact of atypical long-acting injectable versus oral antipsychotics on rehospitalization rates and emergency room visits among relapsed schizophrenia patients: a retrospective database analysisAntipsychotic adherence patterns and health care utilization and costs among patients discharged after a schizophrenia-related hospitalizationPatient and prescriber perspectives on long-acting injectable (LAI) antipsychotics and analysis of in-office discussion regarding LAI treatment for schizophreniaAdherence to antipsychotics among Latinos and Asians with schizophrenia and limited English proficiency.[Risk factors for treatment adherence in patients with schizophrenia: case-control study].Baseline characteristics and hospitalizations in patients with schizophrenia receiving olanzapine long-acting injection: an interim analysis from a non-interventional, prospective observational safety studyPrevalence and predictors of sub-optimal medication adherence among patients with severe mental illnesses in a tertiary psychiatric facility in Maiduguri, North-eastern Nigeria.Results of a pilot cluster randomised trial of the use of a Medication Review Tool for people taking antipsychotic medication.Nurses' perceptions of medication adherence in schizophrenia: results of the ADHES cross-sectional questionnaire survey.Comparison of methods to assess psychiatric medication adherence in methadone-maintained patients with co-occurring psychiatric disorder.Association between adherence to and persistence with atypical antipsychotics and psychiatric relapse among US Medicaid-enrolled patients with schizophrenia.Effects of medication adherence on hospitalizations and healthcare costs in patients with schizophrenia in Thailand.Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophreniaCost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United StatesFactors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.Treatment patterns in Medicaid patients with schizophrenia initiated on a first- or second-generation long-acting injectable versus oral antipsychotic.Improving treatment adherence in your patients with schizophrenia: the STAY initiative.
P2860
Q24197685-1F106964-1822-479C-9F6F-BD6D0FA03D94Q27008464-6078EB87-5C2A-4C36-89E8-4B95181865B0Q28302151-C85B3255-9317-475E-855B-3142420F8515Q28728401-CEADB27D-3934-4782-B401-5459D12EA30CQ31038656-03B4822A-49C8-42C5-B113-1BA0EED231C9Q31049583-D9971B42-7315-4239-958D-51CEE6EF59F7Q33440672-8EE7076E-D8BA-449B-A9F9-A219447B8250Q33453819-8C5A7EAD-F98C-40FA-A50E-59EFE917335CQ33522776-E2498F4C-0BA7-4E9F-B258-258FDA35A4A8Q33587010-9EC837DC-B4E9-4903-9003-8615619AC431Q33589087-F7C39A07-C081-483E-B359-F705B12BB1ABQ33633758-0271A075-C873-4E62-BC3C-27E91091EDBDQ33652933-4E9DCFDF-1578-4F51-84B1-BC3496186E51Q33755676-FCAF26CD-7749-46F2-A20D-290AF69C1E57Q33854628-D3474E1D-AC3F-4728-8982-42CFB6E3F572Q33857710-6EF6E0D8-E97E-49FE-ADE4-B27965F46560Q33862078-A4426639-3554-4E52-A73D-35B00C627E86Q34203368-DF029B07-A038-4F0F-87B4-95EEE1A54E26Q34208127-D37DE2A5-E5DC-47D1-ADCA-29DE164D3B83Q34274083-7097317C-C644-42F2-93ED-23C77A3307A0Q34362623-35E116D2-42FC-4132-81CA-59C00F6ECE76Q34389967-31A74181-9F06-4E17-8D35-C7CBB94D64D7Q34588656-4115858B-9DCD-4E41-A2F2-406FF774F4EAQ34982167-342CC798-280A-43EA-82D4-13BFEAD30297Q35008229-8372C0E3-EDB2-4D2C-A20E-6728F2805EC9Q35019258-9BC1D585-3F36-4B99-A448-E06199F5FA96Q35606405-40656FE7-A300-4232-930A-28295699DAA8Q35793302-03EF925E-0C11-4330-B306-7558EDC60642Q35841195-35FC7797-99FD-4E00-89C0-6B681C167E61Q36042870-DFFC203B-0853-4CCC-ACD4-AE935C8D5B19Q36067721-D7ECC26A-9BB4-4148-9046-8F8EA252E448Q36489412-7C66CC63-6291-4935-8ED5-B9A926402284Q36635305-08DFFDE1-4EA7-4E4B-A10E-FDF60DD68CC5Q36670942-7C5E582F-6F2F-4AE7-BD08-E1CF2DF16590Q36683767-69F5303C-AC4D-4E2C-B30B-6D30856607D7Q36755049-0C66CA6A-0016-4AAB-BB7F-72EE3F9206FCQ37185914-954E507B-4945-41F8-BB18-637268DEF6CCQ37441407-A93FD59F-7FAB-4A26-BE15-2464A50CC41DQ37722508-2EEB7BE2-7FD5-43DF-9BE5-36A99B84A83FQ38071595-7703D855-0297-40F4-BED8-512EA445E2A4
P2860
Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Review and analysis of hospita ...... ophrenia in the United States.
@en
type
label
Review and analysis of hospita ...... ophrenia in the United States.
@en
prefLabel
Review and analysis of hospita ...... ophrenia in the United States.
@en
P2093
P356
P1476
Review and analysis of hospita ...... ophrenia in the United States.
@en
P2093
Dale B Christensen
Gordon G Liu
Shawn X Sun
P304
P356
10.1185/030079907X226050
P407
P577
2007-10-01T00:00:00Z